iBio Announces Presentation Highlighting Excellent Glycosylation for Antibodies Manufactured in Vegetation

iBio, Inc.

iBio, Inc.

Knowledge Demonstrating Bigger Glycosylation Homogeneity with the FastPharming® Procedure In contrast to Standard Procedures to be Presented at PEGS Meeting & Expo

BOSTON, May well 02, 2022 (World NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of upcoming-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing Program, announced now that it will present a poster at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Convention & Expo, May 2-5.

Rachel Jordan, PhD, a senior product supervisor at iBio, will present the poster (#P061), titled “Plant-Designed Antibodies Display Remarkable Glycosylation Homogeneity While Retaining Pharmacokinetic Houses,” which highlights:

  • The production of a solitary uniform G0 glycosylation sample, lacking fucose and xylose, of NISTmAb and rituximab when as opposed to Chinese Hamster Ovary (CHO) mobile society produced antibodies, which contain much more heterogeneous glycosylation patterns.

  • Comparability of in vivo rodent pharmacokinetic profiles for NISTmAb and rituximab generated making use of mammalian mobile lifestyle and the FastPharming Program.

  • How immediate, scalable transient expression in plants of significant-top quality mAbs for in vivo studies can significantly shorten the time to realize in vivo proof-of-idea.

Extra info about producing constant, large-excellent antibodies in the FastPharming System could be accessed in a whitepaper below.

About iBio, Inc.

iBio is a developer of up coming-era biopharmaceuticals and a pioneer in sustainable, plant-dependent biologics producing. Its FastPharming® Process combines vertical farming, automatic hydroponics, and novel glycosylation systems to swiftly produce significant-high quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is acquiring proprietary biopharmaceuticals for the treatment method of cancers, as perfectly as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, delivers FastPharming Contract Improvement and Production Expert services along with Glycaneering Enhancement Services™ for advanced recombinant protein design. For far more details, pay a visit to www.ibioinc.com.

Forward-Searching Statements

Selected statements in this press launch constitute “ahead-seeking statements” inside the which means of the federal securities legal guidelines. Words these types of as “might,” “may possibly,” “will,” “ought to,” “feel,” “assume,” “foresee,” “estimate,” “continue on,” “forecast,” “forecast,” “project,” “prepare,” “intend” or related expressions, or statements with regards to intent, perception, or current anticipations, are forward-wanting statements. These ahead-on the lookout statements are based mostly on latest estimates and assumptions and include statements concerning the FastPharming Manufacturing Procedure the means to generate mAbs that contains additional heterogeneous glycosylation patterns as in contrast to other production programs and making mAbs that are equivalent in vivo rodent pharmacokinetic profile as when compared to other production systems. Though the Enterprise thinks these ahead-seeking statements are reasonable, undue reliance must not be put on any these ahead-searching statements, which are primarily based on information and facts accessible to the Organization on the day of this launch. These forward-hunting statements are topic to various challenges and uncertainties, quite a few of which are hard to forecast that could bring about true final results to differ materially from present expectations and assumptions from those people established forth or implied by any ahead-hunting statements. Vital things that could trigger real results to differ materially from recent anticipations involve, among many others, the Company’s ability to establish a scalable manufacturing approach utilizing the Company’s FastPharming Program and the other things talked over in the Company’s filings with the SEC which include the Company’s Once-a-year Report on Variety 10-K for the year ended June 30, 2021 and the Company’s subsequent filings with the SEC on Sorts 10-Q and 8-K. The information in this launch is furnished only as of the date of this launch, and the Organization undertakes no obligation to update any ahead-hunting statements contained in this launch on account of new facts, upcoming activities, or usually, apart from as necessary by regulation.

Get hold of:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580

iBio Inc

Supply backlink

You May Also Like